Emicizumab Prophylaxis in People with Moderate or Mild Hemophilia A Aged ≥40 Years, with and without Comorbidities - Findings from the Phase III HAVEN 6 Study
Jiménez-Yuste, Víctor, Tzeng, Eunice, Lim, Elise, Ventriglia, Giuliana, Shapiro, Amy D., Oldenburg, Johannes, Mahlangu, Johnny
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities - Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY)
Jiménez-Yuste, Víctor, Oldenburg, Johannes, Tzeng, Eunice, Trzaskoma, Ben, Sanabria, Fabian, Mahlangu, Johnny
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Real-World Persistence with and Adherence to Emicizumab Prophylaxis in Persons with Hemophilia a: A Secondary Claims Database Analysis
Mahajerin, Arash, Khairnar, Rahul, Meyer, Craig S., Abbass, Ibrahim M., Wang, Rongrong, Lee, Lucy, Tzeng, Eunice, Raimundo, Karina
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials
Jiménez-Yuste, Víctor, Oldenburg, Johannes, Tzeng, Eunice, Lim, Elise, Sanabria, Fabian, Mahlangu, Johnny
Published in Research and practice in thrombosis and haemostasis (01.03.2024)
Published in Research and practice in thrombosis and haemostasis (01.03.2024)
Get full text
Journal Article
Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience
Callaghan, Michael, Trzaskoma, Benjamin, Ko, Richard H., Lee, Lucy, Patel, Anisha M., Tzeng, Eunice, Shah, Michelle Lynn, Chang, Tiffany Y., Niggli, Markus, Dhalluin, Christophe, Mahlangu, Johnny
Published in Blood (13.11.2019)
Published in Blood (13.11.2019)
Get full text
Journal Article